Tenaya Therapeutics, a clinical-stage biotechnology company, announced the pricing of its underwritten public offering of 50,000,000 total units.
The offering is priced at $1.20 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock.
The gross proceeds of the offering are approximately $60 million.
Offering Details
50,000,000 units priced at $1.20 per unit with a warrant to purchase one share at $1.50. Proceeds approximately $60 million.
Use of Proceeds
Funding ongoing and planned development of clinical and early-stage product candidates TN-201 and TN-401, and for working capital and general purposes.
Book-Running Managers
Leerink Partners and Piper Sandler acted as joint book-running managers for the offering.
- Tenaya aims to discover therapies addressing heart disease causes through its clinical-stage products TN-201 and TN-401.
- The successful offering provides significant capital to advance the development of Tenaya's pipeline and research endeavors.
The pricing of the public offering by Tenaya Therapeutics marks a strategic step towards fulfilling its mission of developing potentially curative therapies for heart disease.